abrdn Life Sciences Investors

# abrdn Life Sciences Investors (HQL)

This closed-ended equity mutual fund is launched and managed by abrdn Inc., an asset management firm headquartered in Philadelphia. The fund invests primarily in public equities across global markets, with a concentrated focus on the life sciences sector. Its portfolio targets companies in biotechnology, pharmaceuticals, diagnostics, managed healthcare, medical devices, hospitals, healthcare information technology, and related services, as well as agriculture and environmental management industries. The fund emphasizes small-cap growth stocks selected through fundamental analysis, evaluating factors including market positioning, management experience, technological capabilities, and capital generation or acquisition potential.

The fund benchmarks its performance against the NASDAQ Biotech Index and the S&P 500 Index, reflecting its dual focus on sector-specific and broader market comparisons. As a closed-ended fund structure, it operates with a fixed number of shares trading on the NYSE under the ticker HQL. The fund was established in February 1992 and is domiciled in the United States. Revenue is generated through management fees charged to fund assets, though specific asset levels and fee structures are determined by fund prospectus disclosures rather than traditional business operations.